Next Generation Biomaterials Discovery

先进的生物材料是针对传染病和癌症、实现再生医学和未来医疗设备的潜力的重要组成部分。一个跨越诺丁汉工程、科学和医学学院的多学科团队，与4个领先的国际集团合作，共同实现了3D材料发现的愿景。如果没有这种超越2D筛选方法的飞跃，我们将错过新的先进材料，因为它们省略了结构，而且往往不能很好地代表体内环境。其目的是使我们能够超越现有有限范围的仿制生物可吸收聚合物药物和细胞递送剂，目前已获得许可用于人体和医疗设备聚合物，以定制被确定为特定应用最佳功能的材料。我们知道，定义化学、硬度、地形和形状可以控制细胞对材料的反应。该计划将专注于以图案化表面、粒子和更复杂的建筑的形式生产和测试这些属性的大型库。将确定新材料在靶向药物输送、再生医学和下一代医疗设备的先进材料方面的应用。3D筛选方法将定义生物材料发现的新格局，并创建发现更有效的先进材料的平台。我们的三个雄心勃勃的应用重点领域提供了高影响力的例子，在这些例子中，我们的生物材料领先于临床开发。这些下游项目将在学术和商业研究项目中进行，这些项目通过合作、许可和成立分支机构等方式获得资金。

Advanced biomaterials are essential components in targeting infectious diseases and cancers, realising the potential of regenerative medicine and the medical devices of the future. A multidisciplinary team spanning Engineering, Science and Medical Faculties in Nottingham, in collaboration with 4 leading international groups has combined to realise the vision of materials discovery in 3D. Without this leap beyond 2D screening methodologies we will miss new advanced materials because they omit architecture and often poorly represent the in vivo environment. The aim is to allow us to move beyond the existing limited range of generic bioresorbable polymeric drug and cell delivery agents currently licensed for use in man and medical device polymers, to bespoke materials identified to function optimally for specific applications. We know that defining chemistry, stiffness, topography and shape can control the response of cells to materials. This programme will focus on producing and testing large libraries of these attributes in the form of patterned surfaces, particles and more complex architectures. New materials will be identified for application in the areas of targeted drug delivery, regenerative medicine and advanced materials for next generation medical devices. The 3D screening methods will define a new landscape in biomaterials discovery and create the platforms through which more effective advanced materials will be discovered. Our three ambitious application focussed areas provide high impact examples in which our biomaterials leads are developed towards exploitation in the clinic. These downstream projects will be carried out in both academic and commercial research programmes funded through partnering, licensing and formation of spin-outs as appropriate.